drugset / Trial / NCT00629135

Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses

NCT00629135

Phase 3 Completed 180 enrolled Hannover Medical School Bayer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is contemplating the antibiotic therapy of intraabdominal abscesses. These abscesses are a serious problem in surgical practice. Associated pathophysiologic effects as for example peritonitis may become life threatening or may lead to extended periods of morbidity with prolonged hospitalization. The objective of the sudy is to evaluate whether the combination of Moxifloxacin and Metronidazole is equivalent to Piperacillin / Tazobactam with regard to clinical outcome and eradication of aerobe and anaerobe pathogens in patients with intra-abdominal abscesses.

Timeline

Start
2005-11-15
Primary completion
2011-08-15
Completion
2011-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Metronidazole Small molecule 500 mg Intravenous
Subject Moxifloxacin Small molecule 400 mg Intravenous
Subject Piperacillin Small molecule 4.5 g Intravenous
Subject Tazobactam Small molecule 4.5 g Intravenous

Indications